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Key points
• In this analysis of two phase III studies (REACH and 
REACH-2), the effects of ramucirumab in relation to age, 
including elderly patients ≥75 years of age, in hepatocel-
lular carcinoma (HCC) are described in detail.
• In patients with HCC and elevated alpha-fetoprotein 
with prior sorafenib use, ramucirumab improved sur-
vival with delayed deterioration of quality of life and an 
acceptable safety profile, irrespective of age, including 
patients ≥75 years of age.
Abstract
Background & Aims: Limited data on treatment of elderly patients with hepatocel-
lular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global 
phase III studies of ramucirumab in patients with HCC after prior sorafenib, where 
patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) 
benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of 
ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespeci-
fied age subgroups (<65, ≥65 to <75 and ≥75 years).
Methods: Individual patient data were pooled from REACH (baseline AFP ≥400 ng/
mL) and REACH-2. Kaplan-Meier and Cox proportional hazards regression methods 
(stratified by study) assessed OS, progression-free survival (PFS), time to progres-
sion (TTP) and patient-reported outcomes (Functional Hepatobiliary System Index-8 
[FHSI-8] score).
Results: A total of 542 patients (<65 years: n = 302; ≥65 to <75 years: n = 160; 
≥75 years: n = 80) showed similar baseline characteristics between ramucirumab 
and placebo. Older subgroups had higher hepatitis C and steatohepatitis incidences, 
and lower AFP levels, than the <65 years subgroup. Ramucirumab prolonged OS in 
patients <65 years (hazard ratio [HR], 0.753; 95% CI 0.581-0.975), ≥65 to <75 years 
(0.602; 0.419-0.866) and ≥75 years (0.709; 0.420-1.199), PFS and TTP irrespective 
of age. Ramucirumab showed similar overall safety profiles across subgroups, with a 
consistent median relative dose intensity ≥97.8%. A trend towards a delay in symp-
tom deterioration in FHSI-8 with ramucirumab was observed in all subgroups.
Conclusions: In this post-hoc analysis, ramucirumab showed a survival benefit across 
age subgroups with a tolerable safety profile, supporting its use in advanced HCC 
with elevated AFP, irrespective of age, including ≥75 years.
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1  | INTRODUC TION
Hepatocellular carcinoma (HCC) is a relatively common cancer asso-
ciated with significant morbidity and mortality.1-3 In eastern Asia and 
Africa, HCC usually presents in younger patients, whereas in Japan 
and Western countries, HCC generally presents at an older age. This 
is partly because of differences in aetiology across regions. The risk of 
HCC increases with advancing age.1-3 Different definitions exist to de-
fine “elderly”; however, 65 years is most commonly used; in recent HCC 
clinical trials, patients ≥75 years of age were considered.4 In developed 
countries, increasing life expectancy is leading to a progressively aging 
population, resulting in higher numbers of elderly patients with HCC.4,5
Elderly patients are often fragile, have comorbidities, altered 
drug pharmacokinetics and a poor prognosis. Treatment of el-
derly patients with HCC remains an unresolved clinical challenge, 
with increasing unmet need, especially for those ≥70 years of 
age.4-6 Despite recently available data supporting the efficacy of 
multitargeted tyrosine kinase inhibitors (mTKIs),4-9 single-agent im-
mune checkpoint inhibitors (CPI)10,11 or CPI in combination with an 
anti-angiogenic agent,12 data for elderly patients are scarce. Of note, 
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where data are available, the use of mTKIs is associated with sig-
nificant adverse effects4,6,13 or unknown toxicity profiles8,9 in this 
population. Most global trials enrol younger or fit older adults, which 
limits the application of their results to older adults in clinical prac-
tice. Additionally, most HCC treatment guidelines offer no specific 
guidance for the treatment of elderly patients owing to limited evi-
dence-based data.4,5
Ramucirumab, a human immunoglobulin G1 monoclonal anti-
body that inhibits ligand activation of vascular endothelial growth 
factor receptor 2 (VEGFR2), was assessed for efficacy and safety 
vs placebo in patients with HCC after prior sorafenib in two global, 
randomized, double-blind, placebo-controlled phase III clinical tri-
als (REACH and REACH-2).14,15 A prespecified subgroup analysis 
of patients with HCC with baseline alpha-fetoprotein (AFP) levels 
≥400 ng/mL in REACH showed a significant overall survival (OS) 
benefit in this subgroup (hazard ratio [HR], 0.67; 95% confidence 
interval [CI], 0.51-0.90)15; this was confirmed in the REACH-2 trial 
(HR, 0.710; 95% CI, 0.531-0.949; P = .0199), without compromising 
patient-reported disease symptoms as assessed by the Functional 
Assessment of Cancer Therapy (FACT) Hepatobiliary Symptoms 
Index (FHSI)-8.14 Ramucirumab had an acceptable safety profile in 
these trials and therefore may be considered for HCC treatment 
in elderly patients. This post-hoc analysis evaluated the efficacy, 
safety and patient-reported outcomes (PROs) for ramucirumab in 
three prespecified age subgroups (<65, ≥65 to <75 and ≥75 years of 
age) using the pooled data of patients with baseline AFP ≥400 ng/mL 
from the REACH and REACH-2 trials.
2  | METHODS
2.1 | Study design and population
The REACH and REACH-2 study designs have been published else-
where.14,15 Both trials enrolled adults ≥18 years of age with histo-
pathologically or cytologically confirmed HCC (or a diagnosis of 
cirrhosis and HCC with classical imaging characteristics), previously 
treated with sorafenib (≥14 days) that was discontinued because of 
disease progression/intolerance, Barcelona Clinic Liver Cancer stage 
B/C disease, Child-Pugh class A liver disease and Eastern Cooperative 
Oncology Group (ECOG) performance status 0 or 1. Both trials had 
similar eligibility criteria, except patients in REACH-2 had to have 
baseline AFP ≥400 ng/mL. Individual patient data (stratified by 
study) from REACH (AFP ≥400 ng/mL) and REACH-2 were pooled 
for this post-hoc analysis, which substantially increased the sam-
ple size, thus enabling a more precise assessment of ramucirumab 
treatment effect by different age groups. Both pooled analyses and 
age cut-off values of 65 and 75 years were prespecified in the pro-
tocol before REACH-2 database lock. Both trials were conducted 
in accordance with the Declaration of Helsinki and International 
Conference on Harmonisation Guideline for Good Clinical Practice. 
The ethical review board of each participating site approved the 
protocol. All patients provided informed consent before treatment. 
Both trials were registered at www.clini caltr ials.gov (NCT01140347, 
NCT02435433).
2.2 | Treatment and procedures
Patients were randomly assigned (1:1 ratio in REACH; 2:1 ratio in 
REACH-2) to receive ramucirumab or placebo. In REACH, randomi-
zation was stratified by geographical region and aetiology of liver 
disease (hepatitis B vs hepatitis C vs other aetiologies).15 In REACH-
2, randomization was stratified by macrovascular invasion, geo-
graphical region and ECOG performance status.14 Patients received 
ramucirumab (8 mg/kg) or placebo intravenously on Day 1 of each 
14-day cycle plus best supportive care until disease progression, un-
acceptable toxicity or withdrawal of consent. Tumour response was 
assessed every 6 weeks during the first 6 months and every 9 weeks 
thereafter, according to Response Evaluation Criteria in Solid Tumors 
v1.1. The FHSI-8 was used to assess PROs.16 Estimates of exposure 
(minimum concentration after administration of first dose [Cmin,1]) 
were calculated using population pharmacokinetic analysis.17
2.3 | Statistical analyses
This post-hoc analysis of pooled individual patient data (stratified by 
study) from REACH (patients with baseline AFP ≥ 400 ng/mL) and 
REACH-2 assessed the efficacy, safety and health-related quality of 
life outcomes for ramucirumab vs placebo in three prespecified age 
subgroups (<65, ≥65 to <75 and ≥75 years of age). Efficacy was as-
sessed in all randomized patients with baseline AFP ≥ 400 ng/mL. 
Survival curves and medians with 95% CIs for OS, progression-free 
survival (PFS) and time to progression (TTP) were estimated using 
the Kaplan-Meier method, with the stratified (by study) Cox re-
gression model used to estimate HRs. Deterioration in FHSI-8 was 
defined as a ≥3-point decrease in total score. Time to deterioration 
(TtD) was defined as time from randomization date to deterioration 
date. Safety was assessed in all patients who received at least one 
dose of study drug. Treatment-emergent adverse events (TEAEs) 
were graded using Common Terminology Criteria for Adverse 
Events (CTCAE) v4.0. Analyses were conducted using SAS® 9.4 (SAS 
Institute Inc, Cary, NC, USA).
3  | RESULTS
3.1 | Demographic and baseline clinical 
characteristics
This subgroup analysis included 542 patients with AFP ≥400 ng/
mL (REACH: 250; REACH-2:292). All randomized patients re-
ceived study treatment and were included in the efficacy and 
safety analyses. Baseline characteristics were generally similar 
between treatment arms and across the age subgroups (Table 1). 
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However, patients <65 years of age had higher incidences of 
hepatitis B and extrahepatic spread and higher median baseline 
AFP, whereas steatohepatitis was higher in the older subgroups 
(Table 1).
3.2 | Treatment exposure
The median relative dose intensity (RDI) of ramucirumab was con-
sistently high (≥97.8%) in the three age subgroups (Table 2). Similarly, 
TA B L E  1   Baseline demographic and disease characteristics of the pooled REACH (AFP ≥400 ng/mL) and REACH-2 age subgroups














Male 83.6 82.4 71.0 86.6 71.2 82.1
Geographical region (%)
America, Europe, Israel, 
Australia
39.8 35.1 59.1 64.2 59.6 67.9
Asia (excluding Japan) 46.2 52.7 17.2 10.5 11.5 7.1
Japan 14.0 12.2 23.7 25.4 28.9 25.0
ECOG PS (%)
0 57.3 51.2 54.8 52.2 46.2 57.1
Child-Pugh score A-5 (%) 63.2 64.9 58.1 55.2 53.8 46.4
Baseline BCLC stage C (%) 87.1 90.1 84.9 86.6 82.7 75.0















Aetiology of liver disease 
(%)
Hepatitis B 56.7 61.1 21.5 28.4 13.5 10.7
Hepatitis C 22.8 23.7 28.0 26.9 34.6 25.0
Significant alcohol use 18.1 16.0 26.9 28.4 28.8 10.7
Steatohepatitis (NASH, 
fatty liver)
3.5 3.1 12.9 4.5 15.4 14.3
Others 12.3 6.1 15.1 19.4 19.2 35.7
Presence of macrovascular 
invasion (%)
33.9 35.9 37.6 31.3 38.5 32.1
Presence of extrahepatic 
spread (%)
79.5 80.9 62.4 74.6 61.5 53.6
Duration of prior sorafenib 
treatment, months
Mean 6.7 6.0 6.4 7.8 6.5 6.2
Median 3.7 3.5 3.5 5.0 4.3 3.7
Reason for sorafenib 
discontinuation, n (%)
Progressive disease 152 (88.9) 116 (88.5) 75 (80.6) 59 (88.1) 47 (90.4) 23 (82.1)
Intolerance 19 (11.1) 15 (11.5) 18 (19.4) 8 (11.9) 5 (9.6) 5 (17.9)
ALBI grade, n (%)
Grade 1 82 (48.0) 60 (45.8) 33 (35.5) 27 (40.3) 21 (40.4) 8 (28.6)
Grade 2 87 (50.9) 65 (49.6) 60 (64.5) 36 (53.7) 29 (55.8) 19 (67.9)
Grade 3a  1 (0.6) 3 (2.3) 0 3 (4.5) 0 0
Missing 1 3 0 1 2 1
Abbreviations: AFP, alpha-fetoprotein; ALBI, Albumin-Bilirubin; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group 
performance status; NASH, non-alcoholic steatohepatitis.
aSubjects with ALBI grade 3 were from the REACH study only. 
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the estimated mean minimum ramucirumab concentration (Cmin,1) 
was comparable across the age subgroups (≥24.1 ng/mL) (Table S1). 
The proportion of patients requiring a ramucirumab dose adjustment 
was similar in the subgroups (<65 years: 31% vs ≥65 to <75 years: 
36.6% vs ≥75 years: 38.5%) (Table 2). Most dose adjustments were 
as a result of TEAEs. The median number of treatment cycles was 5, 
5 and 7 in the <65, ≥65 to <75 and ≥75 years subgroups respectively.
3.3 | Efficacy
Ramucirumab prolonged OS vs placebo, with similar median OS in 
all three age subgroups (<65 years: 8.18 vs 4.76 months [HR, 0.753; 
95% CI, 0.581-0.975]; ≥65 to <75 years: 7.62 vs 5.22 months [HR, 
0.602; 95% CI, 0.419-0.866]; ≥75 years: 8.87 vs 6.31 months [HR, 
0.709; 95% CI, 0.420-1.199]) (Figure 1). In the three age subgroups, 
compared with placebo, ramucirumab also improved PFS (<65 years: 
2.73 vs 1.45 months [HR, 0.613; 95% CI, 0.472-0.796]; ≥65 to 
<75 years: 2.78 vs 1.84 months [HR, 0.563; 95% CI, 0.396-0.802]; 
≥75 years: 4.17 vs 1.64 months [HR, 0.480; 95% CI, 0.282-0.817]) 
(Figure 2) and TTP (<65 years: 2.76 vs 1.45 months [HR, 0.591; 95% 
CI, 0.447-0.782]; ≥65 to <75 years: 2.79 vs 1.87 months [HR, 0.555; 
95% CI, 0.377-0.818]; ≥75 years: 4.17 vs 2.04 months [HR, 0.443; 
95% CI, 0.255-0.769]) (Figure 3). Post-discontinuation systemic ther-
apies (PDT) were generally balanced between treatment arms, but 
the rate of overall PDT use was lower in elderly patients (≥75 years: 
19.2%) than younger patients (<65 years: 32.2%; ≥65 to <75 years: 
33.3%) (Table S2).
3.4 | Safety
The overall safety profile of ramucirumab, including incidences 
of grade ≥3 TEAEs, was comparable between the <65 and ≥65 to 
<75 years subgroups (Table 3). In the ≥75 years subgroup, the inci-
dence of grade ≥3 TEAEs (hypertension and fatigue) was higher for 
ramucirumab (62%) than placebo (39%), but was comparable with 
ramucirumab in the two younger subgroups (54% and 60%) (Table 3). 
Common TEAEs leading to dose adjustments in the ramucirumab arm 
were proteinuria in patients <65 years of age (4.1%) and hyperten-
sion in the two older subgroups (7.5% and 5.8%). Adverse events of 
special interest in the ramucirumab arm, based on its known safety 
profile, were comparable between the age subgroups (Table S3).
3.5 | Patient-reported outcomes
A trend for a delay in the deterioration of symptoms as measured 
by FHSI-8 was observed in the ramucirumab arm across all age sub-
groups but was not statistically significant. Median TtD was numeri-
cally longer in the ramucirumab vs the placebo arms in all three age 
subgroups (Figure 4).
4  | DISCUSSION
This is the first detailed report that describes the efficacy, safety 
and PROs of a systemic drug in relation to age in HCC, including pa-
tients ≥75 years of age, in a clinical trial setting. Although mTKIs like 
lenvatinib and regorafenib have shown similar efficacy outcomes, 
and cabozantinib has shown similar efficacy and safety profiles18 
between patients with HCC aged <65 years vs those ≥65 years old, 
these retrospective reports did not further divide the elderly age 
groups, and the specific effects of these mTKIs in patients ≥70 and 
≥75 years of age are unknown.5-8 This post-hoc subgroup analysis in 
patients with HCC and AFP ≥400 ng/mL, who had progressed on or 
were intolerant to sorafenib, showed a survival benefit (improved 
OS, PFS and TTP) for ramucirumab and a comparable estimated 
ramucirumab exposure across three prespecified age subgroups, 
including ≥75 years, with a manageable safety profile and a trend 
for improvements in PROs. This finding is consistent with the sub-
group analyses from the phase III placebo-controlled REGARD and 
RAINBOW studies, which showed a survival benefit of ramucirumab 
as monotherapy or in combination with paclitaxel in elderly patients 
(≥70 and ≥75 years of age) with advanced gastric cancer.19 Together, 
these results suggest that ramucirumab can be used in patients with 
HCC irrespective of age, including elderly patients ≥75 years of age.
Overall, ramucirumab had an acceptable safety profile across 
all three age subgroups, which is consistent with the previously 
reported safety profile of ramucirumab.20 The higher incidence of 
grade ≥3 TEAEs (ie hypertension and fatigue) with ramucirumab in 
the ≥75 years subgroup may be owing to slightly longer treatment 
duration in this subgroup, allowing more time for recording TEAEs. 
Use of mTKIs in elderly patients is associated with significant ad-
verse effects4,6,18 or unknown toxicity profiles.8,9 Ramucirumab 
may offer a favourable safety profile for elderly patients with HCC, 
particularly for hand-foot syndrome, diarrhoea and fatigue, which 
are common side effects of mTKIs in elderly patients.13 Additionally, 
the median RDI (≥97.8%) and treatment duration for ramucirumab in 
the current analyses were maintained irrespective of age, suggest-
ing good treatment administration compliance, and the proportion 
of patients requiring a dose adjustment in the ramucirumab arm was 
similar between the age subgroups, indicating favourable treatment 
tolerance.
The aetiology of HCC may affect treatment response.4,6 In this 
analysis, patients <65 years of age were more likely to have hepati-
tis B–related HCC vs older patients, who were more likely to have 
hepatitis C–related HCC. This is consistent with previously de-
scribed characteristics of HCC in young and elderly patients.4-6,21 
Longer treatment duration for ramucirumab in the ≥75 years of age 
subgroup than in the younger subgroups may be attributed to lower 
AFP levels in the ≥75 years subgroup, which are associated with less 
aggressive tumour types and a better prognosis (Tables 1 and 2). 
Finally, different geographical regions may be associated with dif-
ferent patient characteristics for age, HCC aetiology and AFP levels 
and, therefore, different treatment outcomes.
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Comprehensive PRO data are lacking from randomized con-
trolled trials of targeted therapy in HCC.22 Some recent phase III 
trials in HCC have reported on quality of life; however, the use of 
different methodologies in these studies makes their interpretation 
difficult.8,9,22 In this analysis, the effect of ramucirumab on PROs did 
not appear to be influenced by age, with a trend towards a delay in 
deterioration of symptoms (as assessed by FHSI-8) in all three age 
subgroups.
One of the strengths of this study is the use of pooled individ-
ual patient data from two similarly designed phase III trials, which 
substantially increased the sample size. Additionally, the age sub-
groups were prespecified. However, several aspects of this analy-
sis represent notable limitations that reduce the robustness of the 
results. The main limitation is the post-hoc nature of this analysis, 
which was not designed or powered to show differences between 
ramucirumab and placebo across the age subgroups. Additionally, 
the number of patients in each subgroup, especially in the old-
est subgroup (≥75 years), is limited, and the three subgroups are 
highly heterogeneous with respect to patient baseline character-
istics. Another important limitation is the nature of the clinical 
trial, which underrepresents elderly patients and may have led to 
selection bias. Selection of elderly patients suitable for clinical 
trials for cancer treatments should be performed using appro-
priate geriatric assessments.23 Therefore, these results must be 
interpreted with caution in clinical practice. Furthermore, the im-
plications of these results in elderly non-Japanese Asian patients 
remain to be defined because of their underrepresentation in this 
study.
In conclusion, this post-hoc subgroup analysis in patients with 
HCC and elevated AFP, who had progressed on or were intolerant 
to sorafenib, showed that ramucirumab had a survival benefit with 
a trend for a delay in deterioration of PROs, irrespective of age, in-
cluding patients ≥75 years of age. The overall safety profile of ramu-
cirumab was comparable across the three age subgroups, with a high 
median RDI and similarly maintained treatment duration irrespective 
of age. Therefore, ramucirumab may offer an active and well-toler-
ated treatment option for elderly patients with HCC and elevated 
AFP levels. This post-hoc analysis provides valuable information for 
the treatment algorithm of elderly patients with HCC, especially 
those ≥75 years of age.
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F I G U R E  1   Kaplan-Meier plots of OS 
for patients receiving ramucirumab or 
placebo in the pooled REACH (patients 
with AFP ≥400 ng/mL) and REACH-2 
age subgroups: (A) <65 years, (B) ≥65 
to <75 years and (C) ≥75 years. CI, 
confidence interval; HR, hazard ratio; OS, 
overall survival
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38
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n = 171 n = 131
Median, mo (95% CI) 8.2 (6.5-9.4) 4.8 (4.1-6.4)
34.8 (27.4-42.3) 23.8 (16.6-31.8)
Stratified HR (95% CI) 0.753 (0.581-0.975)
12-month OS rate, % (95% CI)
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n = 93 n = 67
Median, mo (95% CI) 7.6 (5.8-11.2) 5.2 (4.1-6.2)
38.2 (27.9-48.3) 16.0 (7.9-26.6)
Stratified HR (95% CI) 0.602 (0.419-0.866)
12-month OS rate, % (95% CI)
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38
52 48 46 33 27 21 14 12 12
28 26 19 15 11
14 12 11 8 5 1 0 0 0 0 0 0
06 6 5 4 1 1 1 1 1 0 0 0 0
8 4 1 1 0 0 0 0 0 0 0





























n = 52 n = 28
Median, mo (95% CI) 8.9 (6.0-11.6) 6.3 (3.4-8.4)
32.0 (19.5-45.2) 25.0 (11.1-41.8)
Stratified HR (95% CI) 0.709 (0.420-1.199)
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F I G U R E  2   Kaplan-Meier plots of PFS 
for patients receiving ramucirumab or 
placebo in the pooled REACH (patients 
with AFP ≥400 ng/mL) and REACH-2 
age subgroups: (A) <65 years, (B) ≥65 
to <75 years and (C) ≥75 years. CI, 







0 2 4 6 8 10 12 14 16 18 20 22 24 26





























n = 171 n = 131
Median, mo (95% CI) 2.7 (2.0-2.7) 1.5 (1.4-1.6)

















0 2 4 6 8 10 12 14 16 18 20 22 24 26


















n = 93 n = 67
Median, mo (95% CI) 2.8 (2.5-4.0) 1.8 (1.4-2.7)
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F I G U R E  3   Kaplan-Meier plots of TTP 
for patients receiving ramucirumab or 
placebo in the pooled REACH (patients 
with AFP ≥400 ng/mL) and REACH-2 
age subgroups: (A) <65 years, (B) ≥65 
to <75 years and (C) ≥75 years. CI, 
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F I G U R E  4   Kaplan-Meier plots of time 
to deterioration in FHSI-8 total scores 
for patients receiving ramucirumab or 
placebo in the pooled REACH (patients 
with AFP ≥400 ng/mL) and REACH-2 
age subgroups: (A) <65 years, (B) ≥65 
to <75 years and (C) ≥75 years. CI, 
confidence interval; FHSI-8, Functional 
Assessment of Cancer Therapy 
Hepatobiliary Symptom Index-8; HR, 
hazard ratio; NE, not evaluable
Placebo
Ramucirumab
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